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Background: Human cystatin C (HCC) is a potential biomarker for tubular damage and impaired renal function. It
is difficult to obtain efficient paired monoclonal antibodies against HCC with low molecular to meet the
requirements for clinical application The present study was to establish a stable and repeatable measurement for
HCC with self-made monoclonal antibodies (McAbs) and Variable domain of heavy chain of heavy-chain antibody
(VHHs) increase the sensitivity.
Methods: With hybridoma technology and phage display technology: R-HCC as a screening antigen and N-HCC as
the detector for antigens to obtain the specific antibody and established an enzyme-linked immunosorbent assay
for human cystatin C using self-made McAbs and VHHs.
Results: We have successfully obtained three McAbs; 5 F2, 4E4, 1E11 and four VHHs; 3-2, 3-24, 3-33 and 4-5 which
were specific for HCC. The measurement of HCC was established with the self-made monoclonal antibodies and
VHHs with a high sensitivity the lower limit of detection at 0.5 ng/ml and the detection range at 0.5 ~ 31.3 ng/ml.
Conclusion: Our data provides a new approach for paired antibody screening and testing of the small molecular
biomarker with a single dominant epitope, with the important biological and clinical significance.
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Renal insufficiency is an important influencing factor for
the prognosis of patients with chronic heart failure and
more accurate detection of mild renal impairment may
improve the risk stratification of the patients, especially
with the early impairment of renal function. Circulating
levels of creatinine are considered as one of the common
readouts to estimate glomerular filtration rate (GFR), an
important evaluation index of renal function [1-4]. Cir-
culating levels and endogenous clearance of creatinine
are used to clinically detect GFR, while there are many
factors influencing the accuracy [5,6]. Some reports of
early nephropathy demonstrated that cystain C has high* Correspondence: tianhao74@hotmail.com; yaogang@sibs.ac.cn
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unless otherwise stated.sensitivity and specificity in glomerular filtration rate
detection [7,8]. Cystatin C, a non-glycosylated protein, is
produced continuously by all cells in organs/tissues. It is
filtered in the renal glomeruli and completely reabsorbed
by the renal tubuli. Alterations of serum cystatin C were
considered as an early renal marker in diabetic patients
[8-11], cardiovascular diseases kidney transplantation,
hyperthyroidism, cancer, or others [12-15]. The detec-
tion of cystatin C was further improved for early diagno-
sis of serious diseases, with the potential of social and
economic significance [16-20].
Cystatin C as the primary biomarker to estimate GFR
and kidney function was measured in serum, plasma,
cerebrospinal fluid, or urine [21-26]. The aim of the present
study was to establish a new Double-Antibody-Sandwich
Enzyme-Linked immunosorbent assay(DAS-ELISA)-based
measurement of HCC with the self-made monoclonal
antibody and VHHs by applying the hybridoma technol-
ogy and phage VHH display technology, to develop atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cost, and easy operation.
Methods
Reagents and instruments
Nucleic acid gel imaging system, nucleic acid electro-
phoresis apparatus and protein gel electrophoresis ap-
paratus were purchased from Shanghai Tanon company.
Microplate reader was purchased from Thermo Fisher
Technology Ltd (Shanghai, China). Polyethylene glycol
(PEG) was purchased from Merck Co, Mouse typeriso-
typing panel kit from Bio-RAD Co, and RPMI MEDIEM
1640 medium, penicillin-Streptomycin double antibody
solution, newborn calf serum and HEPES from Life Tech-
nologies Gibco Co. Hypoxanthine-Aminopterin-Thymidine
(HAT) supplemented medium, Hypoxanthine- Thymidine
(HT) supplemented medium, Freund's complete or incom-
plete adjutants were purchased from Sigma. Natural human
cystatin C (N-HCC) was purchased from Enzo Life
Sciences Ltd., Horseradish peroxidase-conjugated goat
anti-mouse IgG from Santa Cruz Biotechnology Inc.,
or Tween-20 and Bovine serum albumin (BSA) from
Amresco. BALB/c mice were from Shanghai Institutes
for Biological Nutrition, according to the ethical permis-
sion approved by the committee of Animal Ethical
Evaluation, Chinese Academy of Science. The natural
camel single-domain heavy chain antibody library was
kindly provided by Dr. Ario de Marco for Italian IFOM-
IEO center.
Preparation of recombinant HCC
The total RNA was extracted from renal epithelial 293 T
cells using the TransZol Up RNA kit. The cDNA was
synthesized from RNA using the Superscript II reverse
transcriptase with OligodT (18) primers, as the template
for the PCR reaction. The primers specific for HCC were
used to introduce the restriction sites BamH I and Xho I
(The primers: 5’-GGATCCAGTCCCGGCAAGCCG-3’
and 5’-CCTCGAGCTAGGCGTCCTGACAGGT-3’). PCR
products (363 bp) corresponding to HCC fragments and
then connected to pEASY-T1 simple T vectors [27-29].
The cloning T vectors which contain purpose gene and
the prokaryotic expression vector pET-32a was digested
with BamH I and Xho I twice and dephosphorylated and
gel purified before the ligation incubation. The ligation
was performed overnight at 16°C by T4 DNA ligase. The
recombinant plasmids were transformed into Rosetta and
the transformants were selected on Luria-Bertani LB agar
plates supplemented with 100 μg/ml ampicillin. Single
bacterial colony was picked from the transformned plate
and verified by PCR, and the positive bacteria were in-
duced to express the target protein. The positive single
colonies inoculated (1:100) into 10 ml of LB liquid media
containing 100 μg/ml ampicillin as appropriate. Bacterialcultures were incubated at 37°C overnight with shaking
and then inoculated into 1 L of fresh antibiotic-containing
Luria-Bertani (LB). Isopropyl thio-β-D-galactose glycoside
(IPTG) was added to a final concentration of 0.5 mM to
induce protein expression. Bacteria were harvested by
centrifugation (8000 r/min, 10 min, 4°C) and pellets were
re-suspended in 100 ml pre-cold PBS, where phenyl-
methanesulfonyl fluoride(PMSF) was added at 1 mM. Bac-
terial lysate were centrifuged (12,000 r/min, 15 min, 4°C)
and the supernatants were transferred to new tubes, while
the precipitates were re-suspended in PBS [27,30-33]. An
appropriate amount of both the supernatants and suspen-
sions were mixed with an equal volume of 2 × SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel electrophor-
esis) loading buffer. Expression levels of recombinant R-
HCC in supernatants and precipitates were analyzed by
SDS-PAGE analyses. Bacterial samples that were not in-
duced with IPTG, wild-type Rosetta transformed with
pET-32a were used as controls.
The proteins were expressed in an insoluble form as in-
clusion bodies, where 2 M urea was added, ultrasounded,
and hen the lysates were centrifuged (12,000 r/min,
20 min, 4°C). The supernatants were transferred to dia-
lysis bags in PBS and dialyzed overnight at 4°C thrice.
The protein solution was dialyzed at the renaturation of
His-R-HCC more than 80% (wt/wt). The Ni-NTA agar-
ose (Qiagen) was used to purify His-R-HCC according
to the manufacturer’s instructions. Two ml of Ni-NTA
agarose pre-equilibrated with the lysis buffer, including
50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, PH
8.0, was added to the supernatant and gently mixed at 4°C
for 1 h. The lysate agarose mixture was loaded to the
column and washed with the buffer, including 50 mM
NaH2PO4, 300 mM NaCl, and 0.05% (v/v) Tween 20, at
pH 8.0, by the stepwise addition of graduate imidazole
concentrations at 20 mM, 50 mM, 100 mM, 200 mM, or
500 mM, respectively. The protein was eluted using 10 ml
of elution buffer with 50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole at pH 8.0. Concentrations of purified
recombinant proteins were determined by the Bradford
assay [30]. His-tagged proteins were digested by thrombin
and then the ultrafiltration concentrate was analyzed by
SDS-PAGE analyses and Western blot.
Mouse immunization and evaluation of anti R-HCC sera
Four BALB/c female mice (6-8 weeks old) were immunized
with R-HCC by intraperitoneal injections of 100 μL at the
concentration of 1 g/L of R-HCC and 100 μL of Freund's
adjuvant. The first doses contained complete Freund's ad-
juvant, and subsequent doses were given a 3-weeks interval
using incomplete Freund's adjuvant. Blood samples were
collected one week after the fourth injection, and the titer
and specificity of antibody response were determined with
indirect ELISA [34,35].
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Murine myeloma cells were cultured in high-glucose
Dulbecco's minimal Eagle's medium (DMEM) supple-
mented with 20% (v/v) FBS and 1% (wt/vol) penicillin-
streptomycin. Cell fusion procedures were carried out
according to the protocols of the Clonal Cell-HY™ kit.
Mouse spleen lymphocytes were mixed with the mye-
loma cells at the ratio of 5:1 using 1 ml of PEG 4000.
The fused cells were then transferred into a tissue cul-
ture plate containing the methycellulose-based selection
medium and incubated. The individual hybridoma clones
in the semisolid medium were transferred into a 96-well
plate about 12 days after the cell fusion. The supernatants
were collected when hybridoma cells were grown to ap-
proximately 10-20% (v/v), and initial screening was per-
formed using indirect ELISA. The screen yielded positive
hybridoma cells, which were subsequently sub-cloned
thrice by the limiting dilution. Aliquots of first hybrid-
omas and the clones were cryopreserved at several stages
during the development.
Purification and characterization of monoclonal
antibodies (McAbs)
Female BALB/c mice were intraperitoneally injected
with 106 hybridoma cells 7 days after intraperitoneal in-
jection with 0.5 ml of liquid olefin. After 14 days, ascites
fluid was collected 14 days after the injection with cells
and centrifugated at 4000 r/min for 15 min. McAbs were
purified from mouse ascites by ammonium sulfate precipi-
tation followed by affinity chromatography on a protein G
column [30,34-37]. Classes and subclasses of McAbs were
identified by mouse monoclonal antibody isotyping re-
agents (Sigma-Aldrich) following the manufacturer’s in-
structions [33].
Determination of McAbs Affinity
The affinity constants of McAbs were detected after sam-
ple preparation, chip surface pretreatment, sample injec-
tion, regeneration, and data analysis. Three μg of natural
Human cystatin C (N-HCC) and 0.05 M PBS at 7.4 was
prepared and filtered. Our pilot experiments showed that
the isoelectric point of 9.0 HCC was bonded to the surface
of CM5 chip in HCl-glycine buffer at pH = 4.5. Three μg
HCC was dissolved in 200ul of HCl-glycine buffer to be
fully integrated on the CM5 sensor, and then equilibrated
with PBS overnight. The chip was regenerated and then
finished, followed by data analysis.
Selection of phage displayed VHHs
R-HCC was coated overnight at 4°C in 4 ml Nunc-
Immuno™ or Maxisorp™ tubes at a concentration of 30 μg/
ml using 50 mM sodium carbonate buffer thrice before
the addition of 3 × 1015 phages for the first round of pan-
ning after the blocking. Tubes were washed 10 times withPBS 0.05% Tween and PBS after 30 min rocking and
90 min standing upright at room temperature, and bound
phages were eluted with 10 mM HCl, pH 2.0. Eluted
phages were neutralized by Tris–HCl, pH 8.0 and then
used to infect TG1 cells at 37ºC for 40 min. Infected
cells were harvested by centrifugation and The new sub-
library of phages was resuspended, titrated, and used in
the second round of panning [38,39]. The procedure
was repeated and the enrichment of the phage subli-
brary obtained was calculated as the ratio of output/in-
put phages.
Screening of VHHs by ELISA
Individual colonies from the dilution series were tested
for antigen binding by phage ELISA [38,39]. Tubes
containing 1 ml of 2× TY medium were inoculated with
10 μl of the overnight culture. After then, 2 × 1012 KM13
helper phages were added, mixed, and incubated for 1 h.
Discard supernatant and resuspend pellets in 5 ml of 2 ×
TY medium, incubated for about 18 h, and then separated
and transferred. The phage clones were tested as de-
scribed previously [34,39]. Maxisorp 96-well plates (Nunc)
were coated with HCC and added the antigen at 1 μg/ml.
Plates were washed with PBST and treated with anti-M13
McAb HRP conjugated for 1 h at 37°C, and added with
100 μl of TMB solution after PBST washing. Plats were
analysed at 450 nm in a microplate reader. Clones with an
absorbance value highest were considered positive and the
sequences analyzed to identify unique binders.
Purification and characterization of VHHs
Clones with unique sequence were subcloned into pET-
28a vector to obtain His-tagged recombinant VHH binders
after transformation into Rosetta competent cells. The
supernatant was purified by nickel column affinity chroma-
tography directly [30,39]. The purity of the VHH solutions
was confirmed by 12% SDS gel electrophoresis and coo-
massie blue staining. The property of the purified VHH
was determined by ELISA and Western Blotting.
Determination of VHHs’ Affinity
The affinity of VHHs was determined as described previ-
ously [34,39]. Plates were coated with N-HCC after block-
ing and washing. The antibody solution at concentrations
below dissociation constant(Kd), 0.5 nM was incubated
with increasing concentrations of R-HCC from 0.1 nM to
1 μM. N-HCC-coated plates were added by 10 μl of the
reaction mixtures, washed with PBST, and added with
100 μl of TMB solution for the readout at 450 nm.
The establishment of DAS-ELISA
The optimized concentrations of HCC paired antibody
with McAb 5 F2 and 1E11, or phage displayed monoclonal
VHHS P-3-2, P-3-24, P-3-33, and P-4-5, were determined
Figure 1 Analysis of the His-tagged R-HCC and VHHs. (A) SDS-PAGE analysis of recombinant His-HCC expressed in Rosetta (DE3), Lane M: the
molecular weight markers; Lane1: purified His-tagged R-HCC. (B) Western blot identification of purified His-tagged HCC using mouse anti-His IgG,
Lane 1: Control; Lane2: purified His-tagged R-HCC. (C) SDS-PAGE analysis of His-tagged R-HCC digested by thrombin and purified by Ni-NTA,
Lane M: the molecular weight markers; Lane1: purified R-HCC. (D) Western blot analysis of purified VHH using mouse anti-His IgG, Lane M: the
molecular weight markers; Lane1: purified VHH 3-2; Lane2: purified VHH 3-24; Lane 3: purified VHH 3-30; Lane 4: purified VHH 3-33; Lane 5: purified
VHH 4-5; Lane 6: purified VHH 4-8.
Table 1 Detection of mouse serum antibody titers by
ELISA kit
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absorbance at 450 nm was measured.
Assay optimization
The concentration of the coating conjugates with McAbs
and VHH phages was optimized by orthogonal test titra-
tion. The capture antibody coated concentrations at 10.0,
5.0, 2.5, 1.0, 0.5, 0.2, and 0.1 μg/ml were used and the incu-
bation concentrations of HCC antigen solution were 20 ng/
ml. HRP-antibody solutions were diluted to 100, 200, 500,
1000, 2000, and 4000. The one with the OD450nm value
closest to 1.0 was selected as the optimal detection concen-
tration and for further assay development.
Determination of assay properties
The properties of the developed assay, e.g. linear range,
sensitivity, accuracy and precision, were validated. The
linear range and sensitivity was determined according to
the making of the standard curve. The HCC standard
solution was diluted into 62.5, 31.3, 15.6, 7.8, 3.9, 2.0,
1.0, 0.5, 0.2, and 0 ng/ml, respectively. The standard
curve was made using the screened 5 F2-P-3-2 detection
kit to detect HCC concentrations. The accuracy of the
kit was assayed and calculated by adding HCC to a
5-fold diluted preparation the urine or serum at stand-
ard concentrations, and detecting the recovery of HCC.
The concentration of HCC in serum samples was also
measured by the turbidimetric immunoassay as the refer-
ence. The concentration of HCC in serum samples mea-
sured by the commercialized kit was 0.63 μg/ml, while the
DAS-ELISA could detect the serum levels of 10, 25, 50,
100, 250, 500, and 1000 fold dilution. The precision of the
DAS-ELISA was calculated with the intra-variability at 30,20, 10, or 5 ng/ml of HCC sample solution for 10 times
and the coefficient of variation(CV) was used to represent
the precision.Results
The gene encoding HCC construct prokaryotic expression
vector Pet-32a-HCC was cloned and expressed in pro-
karyotic system. The Figure 1A,B demonstrated the pro-
tein expression in insoluble inclusion bodies about 80%.
R-HCC was obtained at a concentration of 2.377 mg/ml
and the molecular weight of 17KD, of which the purity
was more than 95% (Figure 1C) for McAbs and VHHs.
Table 1 shows the titer of sera from mice, of which two
mice were more suitable as a mouse hybridoma fusion
after four injections of R-HCC.
Of hybridoma McAbs, McAbs 5 F2, 4E4, or 1E11 had
high affinity with the coefficients at 2.258−9, 2.975−8, or
3.622−9, respectively. The antibody heavy chain is γ chain
subclasses (IgG1), while light chain subclasses are κ chains
(Table 2). The steric orthe same decision epitopes of HCC
was identified in those McAbs.
Ten monoclonal colonies with the highest absorpti-
ometry were picked from the third round and the fourth
Table 2 Characteristics of the anti-HCC McAbs
The cell culture supernatant of HCC McAbs
Number of clones Titer (OD450 ± SD) Antibody subtypes
5 F2 2.513 ± 0.179 IgG1,κ
4E4 2.634 ± 0.087 IgG1,κ
1E11 2.426 ± 0.081 IgG1,κ
1 × 106 of each hybridoma, in 10 ml medium for 2 days, the supernatant was
detected directly by ELISA. Data shown in the Table are the mean value of
three independent experiments.
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2, 3-24, 3-30, 3-33, numbered 4-5, 4-8, were obtained,
respectively, as shown in Table 3. The VHH genes were
expressed in the prokaryotic system and purified. VHH
3-2, 3-24, 3-33, 4-5 could recognize the N-HCC specific-
ally, with the highest affinity for 3-2 (Figure 2A), while
VHH 3-30, 4-8 did not (Figure 1D).
The paired results by sandwich ELISA between McAbs
5 F2, 4E4, or 1E11 were negative. The paired results be-
tween McAbs and VHHs (phages) demonstrated that
McAb 5 F2 and VHH 3-2, 4-5 (VHH phages P-3-2 and
P-4-5) were paired to detect HCC, and showed optimal
effects (Figure 2B). The optimal coating concentration of
5 F2 and the optimal detection dilution of P-3-2 were
5 μg/ml and 1000 times. DAS-ELISA for HCC was
established with the self-made McAbs and VHHs. The
prepared McAbs 5 F2 and VHH phages P-3-2 or P-4-5
were applied for the development of the measurement.
The optimal effect was achieved with the minimum de-
tection of 0.5 ng/ml and the linear range of 0.5 ~ 30 ng/ml.
The accuracy measured by adding HCC to the urine was
listed in Table 4, and the precision measured by adding
HCC to serum was shown in Figure 2C,D.Table 3 Selection of VHH antibodies against HCC














Amino acid sequences of the diverse binders selected after panning. FR (framework
according to Ana Monegal (Ana Monegal, 2009). Each VHH contains 4 FR and 3 CDDiscussion
Cystain C, a 120 amino acid peptide chain with approxi-
mate 13KD, belongs to the family of papain-like cysteine
proteases and has the biological role in the extracellular in-
hibition of Cathepsins. Cystain C is constantly and largely
produced filtered from the glomerular membrane, and
then completely reabsorbed from the proximal tubular
cells. It has been considered as a biomarker candidate of
renal function, although it is difficult to take the paired
antibodies by hybridoma technology [40]. Diagnostic kits
of cystatin C commercially available are mainly based
on the traditional monoclonal antibody to hardly meet
requirements of the clinical application. The present
study developed a new way to detect human serum
cystatin C with high sensitivity and specificity through
the combination of hybridoma technology and phage
display technology.
With the advantage of phage display it is easier than the
traditional methods to get the paired antibody for detec-
tion of HCC and it provides a new strategy for the detec-
tion of HCC and other small molecules. Using R-HCC as
a screening antigen and N-HCC as the detection of anti-
gens, we successfully obtained McAbs and VHHs against
N-HCC with high affinity. The optimal effect can be
achieved with the detectable minimum of 0.5 ng/ml and
the detecting linear range of 0.5 ~ 30 ng/ml, through
continuous optimization of conditions. The developed
ELISA kit can be used to quantitative detection of HCC
in human urine and human serum with the CV preci-
sion <15%. Such pairing can be used for other HCC quan-
titative measurements, such as colloidal gold strip or latex
particle turbidimetric immunoassay method.
HCC can be stable at room temperature for 2 days, 0 ~














region) and CDR (complementarity determining region) were deduced
R.
Figure 2 Determination of VHHs’ Affinity, the establishment of DAS-ELISA and determination of assay properties. (A) The affinity of
VHHs was determined by ELISA, VHHs were serially diluted into PBS (0.1 M, pH7.4) and PBS was used as the blank control. Each point represents
the mean value of triplicate determinations. (B) Detection of HCC by paired test, the best concentration of coated 5 F2 was 5 ug/ml. Each point
represents the mean value of triplicate determinations. (C) Detection of serum HCC by established DAS-ELISA, comparison of HCC level in serum
samples between ELISA value and the standard value. The HCC concentration of the serum samples by the ELISA kit is 0.71 μg/ml, the accuracy
is high. (D) Precision was measured by ELISA kit, the figure showed that intra-variability CV were 4.1%, 4.5%, 7.94% and 10.1%, in line with the
requirements of CV <15%.









0 0.052 0 0.097 1.36 -
1 0.070 1 0.171 2.40 105.60%
2 0.137 2 0.249 3.50 107.20%
5 0.376 5 0.434 6.10 95.10%
10 0.690 10 0.840 11.80 104.40%
25 1.812 25 1.937 27.20 103.40%
30 2.201 30 2.113 29.68 94.40%
The accuracy of HCC detection kit is 94.8%1 from the data of the table.
1Accuracy = 1-{(105.6%-1) + (107.2%-1) + (1–95.1%) + (104.4%-1) + (103.4%-1) +
(1–94.4%)}/6.
2 = C(control), “C” means concentration.
3Recovery = {C(Detected HCC) -C(control)}/C(Standard).
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present study confirmed the reliability and authenticity
of the HCC determination, so further improvements of
HCC measurements can lead to potential social and
economic significance. The combination of the hybrid-
oma technique and phage display technology for screen-
ing of paired antibodies provides a new solution, with
great biological and clinical significance. The cystain C
as a biochemical marker or predictor of GFR offers the
greater sensitivity in detecting an abnormal GFR [41,42].
The present study provides the new measurement of GFR
to monitor the occurrence and progress of renal diseases.
The further works on the application of the clinical
measurement of renal disease and other diseases are
needed [43-45].
Conclusions
The present study developed and validated a new measure-
ment of HCC as a biomarker for clinical measurement of
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the self-made McAbs and VHHs by applying the hybrid-
oma technology and phage VHH display technology with
high sensitivity.
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